The primary mission of the Cancer Clinical Trials Office (CCTO) is to assist The Tisch Cancer Institute (TCI) investigators in the development, conduct, and reporting of innovative clinical research in an efficient, compliant, and scientifically sound manner. The CCTO is composed of regulatory, financial, clinical, study management, compliance, and data management personnel that support investigators and provide uniformity and consistency in clinical research. The CCTO provides management and oversight functions for coordinating, facilitating, and reporting on the cancer clinical trials that complement the Protocol Review and Monitoring System (PRMS). There is a Quality Assurance Program (QAP) responsible for centralized education and training services, subject central registration, auditing, and the development of policy, which supports the TCI Data and Safety Monitoring Committee (DSMC) to ensure data integrity, while promoting subject safety.
Cancer Clinical Trials Office
Oversight of clinical research is intended to ensure that TCI investigators conduct high-quality science in a responsible manner, with minimal risk to patients.
Matthew Galsky, MD
Medical Director, CCTO and Novel Therapeutics Program
Ajai Chari, MD
Associate Medical Director, CCTO
Paula Klein, MD
Associate Medical Director, CCTO
Max Sung, MD
Chair, Data Safety & Monitoring Committee
The CCTO is organized by divisions that provide distinct, well-integrated services under unified leadership reporting to Rosemarie Gagliardi, Associate Dean of Clinical Research Operations. Skilled personnel are available to assist Investigators by providing administrative, regulatory, finance management, study coordination, quality assurance, educational support and data management and reporting.
Executive Director of Clinical Research Administration
Director, Research Information Systems
Associate Director, Clinical Trials Conduct
Assistant Director, Clinical Trials Support Services
Clinical Research Manager, Study Start-Up
Clinical Trials Analyst
Administrative Assistant, CCTO
Clinical research nurses and coordinators have regular assignments with investigators by disease-specific research teams to build expertise in particular areas of oncology.
Solid Tumors and Lymphoma
Bone Marrow Transplant
Malignant Hematology- Myelodysplastic Syndromes (MDS)
Malignant Hematology- Myeloproliferative Diseases (MPD)
Malignant Hematology-Multiple Myeloma
Lynda N. Rath
The Novel Therapeutics Program at the Tisch Cancer Institute was established to facilitate the conduct of early phase cancer clinical trials including first-in-human and biomarker focused proof-of-concept-studies, representing a multi‐disciplinary collaborative effort to maximize both the efficiency and scientific value of early phase clinical investigation while simultaneously bringing the most cutting‐edge therapies to our cancer patients.
To date we have conducted more than sixty Phase 1 clinical trials in Solid Tumors and Malignant Hematology.
Available Resources dedicated to the Novel Therapeutics Program include:
- Fast Track “One Stop Shop”
- Expert Clinical Investigators with dedicated disease‐specific research teams
- Experience with Industry, Cooperative Groups, Investigator Initiated and Consortium Trials
- Network of Basic and Translational Scientists in Cancer Mechanisms and Immunology
For Institutional Resources supporting the Novel Therapeutics Program: Flyer
For more information please contact us directly at 212-824-7288 or e-mail:
The Cancer Clinical Trials Office currently supports three prestigious research consortia:
MAGIC-Mount Sinai Acute GVHD International Consortium: Composed of 10 major stem cell transplant centers in the United States and Europe who are collaborating to use this new scoring system to test new treatments for acute GVHD.
Contact: Rachel Young
MPD-RC- Myeloproliferative Diseases Research Consortium: An international, multi-institutional consortium set up to coordinate, facilitate, and perform basic and clinical research investigating the genetic and cellular mechanisms of the Philadelphia Chromosome (Ph) negative myeloproliferative neoplasms (MPNs).
Contact: Alicia Orellana
MyTRO- Myeloma Translational Research Organization: A unique clinical research organization connecting sites and myeloma patients with promising drugs through clinical trials. MyTRO offers an efficient solution from providing multiple research sites in the tri-state area.
Contact: Schantel Williams